Novel therapeutic targets of metformin: metabolic syndrome and cardiovascular disease

Expert Opinion on Therapeutic Targets
Ricardo Ladeiras-LopesAdelino Leite-Moreira

Abstract

Metformin is a widely used drug in the treatment of type 2 diabetes mellitus (T2DM). However, it is becoming an attractive drug to manage patients with pre-diabetes and to possibly prevent cardiac remodeling and fibrosis and heart failure. In this review, we highlight the novel therapeutic targets of metformin with a special emphasis on cardiovascular disease. We discuss its key mechanisms of action and new signaling pathways that could partially account for its effect. Furthermore, metformin's role in the management of patients with metabolic syndrome is debated, emphasizing its potential to prevent diabetic heart disease. On the other hand, intense research is ongoing to clarify if metformin will be a future drug to target ischemia-reperfusion injury in the setting of myocardial ischemia. In the following years, one should look carefully at basic science results to successfully design and conduct clinical trials, emphasizing patients without full-blown T2DM, but who otherwise might have increased insulin resistance. Topics such as the prevention of cardiac fibrosis and heart failure with preserved ejection fraction, the attenuation of ischemia-reperfusion injury on an acute coronary syndrome and the post-myocardial infarction...Continue Reading

References

Apr 1, 1992·Journal of Clinical Pharmacy and Therapeutics·K Landin-Wilhelmsen
Jan 3, 1989·Diabetes Research and Clinical Practice·H GinJ Aubertin
May 3, 1996·The Journal of Biological Chemistry·E HuB M Spiegelman
Mar 27, 1999·Biochemical and Biophysical Research Communications·Y AritaY Matsuzawa
Apr 25, 2000·Journal of Molecular and Cellular Cardiology·A K JonassenD M Yellon
Apr 12, 2003·Journal of Molecular and Cellular Cardiology·Derek J Hausenloy, Derek M Yellon
Jan 20, 2005·Journal of Internal Medicine·M E Trujillo, P E Scherer
Apr 20, 2005·Lancet·Robert H EckelPaul Z Zimmet
Jun 3, 2005·Metabolism: Clinical and Experimental·Nadjat OuslimaniJean-Louis Beaudeux
Jun 27, 2007·Circulation·Sihem Boudina, E Dale Abel
Aug 19, 2007·Circulation·Jonathan M McGavockLidia S Szczepaniak
Feb 12, 2008·The American Journal of Medicine·Shelley R SalpeterEdwin E Salpeter
May 14, 2008·Current Hypertension Reports·Sanjeev B PatelDaniel Villarreal
Jun 14, 2008·The American Journal of Cardiology·Kazuo EguchiMarco R Di Tullio
Mar 20, 2009·Journal of Cardiovascular Pharmacology·Marta PaivaDerek M Yellon
Jul 23, 2009·European Journal of Echocardiography : the Journal of the Working Group on Echocardiography of the European Society of Cardiology·Hiromi NakaiYutaka Otsuji
Jun 12, 2010·Biological Chemistry·John T HeikerAnnette G Beck-Sickinger
Jul 14, 2010·Journal of the American College of Cardiology·Christine JellisThomas H Marwick
Mar 19, 2011·Journal of the American College of Cardiology·Cesare RussoMarco R Di Tullio
May 6, 2011·Diabetes Care·Bernd Stratmann, Diethelm Tschoepe
Sep 29, 2011·International Journal of Cardiology·Adriana K BurláMario Fritsch Neves
Feb 11, 2012·Journal of the American College of Cardiology·Scott M Grundy
Mar 23, 2012·Nature Reviews. Molecular Cell Biology·D Grahame HardieSimon A Hawley
Mar 27, 2012·American Journal of Physiology. Heart and Circulatory Physiology·Annika TaubeJuergen Eckel
May 11, 2012·Journal of Pediatric Endocrinology & Metabolism : JPEM·Maria Lola Evia-ViscarraJuan Gerardo Reyes-García

❮ Previous
Next ❯

Citations

Aug 30, 2016·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Ray O Bahado-SinghKypros H Nicolaides
Oct 14, 2016·PloS One·Nathalie Thorin-TrescasesAnil Nigam
May 19, 2017·Journal of Molecular Endocrinology·Yu-Guang MaZhong-Wei Wang
May 17, 2019·Expert Review of Clinical Immunology·Chi Chiu Mok
Nov 14, 2019·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Koh OnoUNKNOWN ABLE-MET Investigators
Mar 17, 2018·Molecular Cancer Therapeutics·Sen XuQinglei Gao
Mar 14, 2021·Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society·Roger K W Smith, C Wayne McIlwraith
Jul 11, 2021·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Nahid AlimoradiReihaneh Fatehi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Related Papers

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Aaron P SchulmanFrancesco Rubino
© 2021 Meta ULC. All rights reserved